


Metallomics

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1
2
3
4 **Copper, differently from zinc, affects bradykinin conformation,**
5
6 **oligomerization state and activity**
7
8

9 Irina Naletova,^{1,2} Vincenzo G. Nicoletti,^{1,2*} Danilo Milardi,³ Adriana Pietropaolo,⁴ Giuseppe
10 Grasso^{5*}
11
12
13
14
15

16 1 Dipartimento di Scienze Biomediche e Biotecnologiche “BIOMETEC”, Università degli
17 Studi di Catania, Via S. Sofia 64, 95125 Catania, Italy.

18 2 Consorzio Interuniversitario di Ricerca in Chimica dei Metalli nei Sistemi Biologici
19 (C.I.R.C.M.S.B.), Piazza Umberto I, 1 – 70121 Bari, Italy.

20 3 Istituto di Biostrutture e Bioimmagini, Via Paolo Gaifami 18, 95126 Catania.

21 4 Dipartimento di Scienze della Salute, Università di Catanzaro, Campus Universitario, Viale
22 Europa, 88100 Catanzaro, Italy.
23
24

25 5 Dipartimento di Scienze Chimiche, Università di Catania, Viale Andrea Doria 6, 95125,
26 Catania, Italy.
27
28
29
30
31
32
33
34
35
36
37

38 *Correspondence to:

39 Giuseppe Grasso, Dipartimento di Scienze Chimiche, Università degli Studi di Catania, Viale
40 Andrea Doria 6, 95125, Catania, Italy. e-mail: grassog@unict.it
41
42

43 Vincenzo G. Nicoletti, Dipartimento di Scienze Biomediche e Biotecnologiche “BIOMETEC”,
44 Università degli Studi di Catania, via S. Sofia 64, 95125 Catania, Italy. Email: nicovigi@unict.it
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

The sole role of bradykinin (BK) as an inflammatory mediator is controversial, as recent data also support an anti-inflammatory role for BK in Alzheimer's Disease (AD). The involvement of two different receptors (B₁R and B₂R) could be a key to understand this issue. However, although copper and zinc dyshomeostasis have been demonstrated to be largely involved with the development of AD, a detailed study of the interaction of BK with these two metal ions has never been addressed. In this work, we have applied mass spectrometry, circular dichroism as well as computational methods in order to assess if copper and zinc have the ability to modulate BK conformation and oligomerization. In addition, we have correlated the chemical data with the metals effect on the BK activity analyzed in cell cultures by biochemical procedures.

The biochemical analyses of BK effects on monocyte/macrophage cell culture (THP-1 Cell Line human) in line with the metals effect on BK conformation, showed that the presence of copper can affect the signaling cascade mediated by the BK receptors. The results obtained open to further role of metal ions, particularly copper, in the development and outcome of neuroinflammatory diseases.

The possible implications in AD are discussed.

Key Words

Bradykinin, copper, zinc, oligomerization, Alzheimer's disease, inflammation.

Introduction

Bradykinin (BK) is a peptide containing nine amino acidic residues and is involved in several different biological activities, being a potent inflammatory mediator that is produced in both brain and peripheral cells under pathophysiological conditions such as trauma, stroke, ischemia, and asthma. BK is able to decrease blood pressure, increase vascular permeability and promote the classical symptoms of inflammation such as vasodilation, hyperthermia, edema, and pain.¹ Levels of BK in humans can vary considerably depending on localization (on average, in plasma $[BK] \cong 4 \cdot 10^{-10}$ M, in the brain $[BK] \cong 1 \cdot 10^{-9}$ M)² and on specific conditions (BK concentrations *in vivo* range from 60 pM to ≥ 100 nM in humans).³ It is important to note that we cannot really know the concentration of BK at the cell surface in the vicinity of the receptor and theoretically this concentration could be micromolar in that membrane domain to evoke receptor activation. In pathological conditions, a rise in the level of BK in the respiratory system causes acute respiratory distress syndrome, dry cough, inflammation, and apoptosis via release of proinflammatory mediators such as cytokines and chemokines, while growing evidence also suggests a role for BK and its receptors in Alzheimer's disease (AD).⁴ For example, a significant increase in densities of kinin B1 and B2 receptors in animals submitted to A β infusion was observed in brain regions related to cognitive behavior, suggesting the involvement of the kallikrein-kinin system in AD *in vivo*.⁵ Although BK is well recognized as a potent mediator of inflammation,⁶ a growing set of evidence suggests an anti-inflammatory role for BK in brain tissues.⁷ Indeed, BK applied to neurons can exert inflammatory effects, whereas in glial cells, BK can have a potential protective role for neurons by inhibiting proinflammatory cytokines.⁸ Interestingly, an increase of BK release in brain and cerebrospinal fluid (CSF) was found in rats chronically infused with A β .⁹ However, only a BK degradation product (Arg-Pro-Pro) was found in the brain, indicating the participation of proteases other than angiotensin converting enzyme (ACE) in BK degradation.¹⁰ Moreover, this result indicates that BK degradation products have also to be considered in order to fully understand the

1
2
3 biomolecular role of BK, as generally peptide fragments derived from a precursor protein
4 (cryptides) could have biological roles that are different from the full-length protein.¹¹
5
6

7 From these data it is evident that the exact role of BK and/or BK cryptides in AD is not very clear
8 and further studies targeting the potential interactions of BK with other recognized actors of AD are
9 needed. Particularly, transition metal ions such as copper and zinc have been reported to play an
10 important role in AD. Moreover, metal ion levels as well as metal-mediated oxidative damage to
11 neuronal cells, which generally precedes A β deposition, have been reported to increase with normal
12 aging.¹² These metals accumulate within the plaque deposits and reach concentrations up to 300
13 μ M.¹³ Copper dishomeostasis has been correlated to many pathological states, and a wide range of
14 possible molecular mechanisms and cellular targets have been claimed to be linked to pathological
15 conditions challenged by bad management of copper levels or subcellular distribution. In addition,
16 copper availability/redistribution is known to be responsible of various consequences in the
17 progression of AD (as well as other neurodegenerative diseases), ranging from A β conformational
18 changes and prooxidant reactions to alteration of APP maturation. Indeed, using chelators like
19 clioquinol or PBT2 it has been also proved that observed beneficial effects can be due to prevention
20 of extracellular A β -metal interactions and redistribution of Cu into cells (Prana Biotechnology Ltd).
21 Moreover, these compounds promote cellular copper uptake, and up-regulation of cell signaling
22 cascade involving a number of molecules with known neuroprotective activity.¹⁴⁻¹⁶ For these
23 reasons, the “metal hypothesis of AD” has been consequently proposed, according to which the
24 abnormal interaction between A β and metal ions has to be considered as one of the major culprits
25 for the development of AD.¹⁷ However, if a dyshomeostasis of metal ions occurs in AD, the effect
26 of altered metal ions concentrations and/or redistribution on biomolecules other than A β has to be
27 taken into account to give further insights on the mechanisms at the base of AD. For this reason the
28 interactions of copper and zinc with proteins such as ubiquitin,¹⁸⁻²⁰ BDNF²¹ and proteases²² capable
29 to degrade A β have been recently studied by our group.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 In the literature, some studies focus on the interaction of BK with metal ions.²³⁻²⁶ However, the
4
5 main aim of these studies was related to the design of new artificial catalysts and ACE inhibitors,²³
6
7 or the elucidation of gas phase interactions for unveiling the intrinsic preference of each metal ion
8
9 for particular coordination geometries and ligand types.²⁴ To the best of our knowledge, none of
10
11 these studies focus on the role of copper and zinc in BK conformation and oligomerization and how
12
13 these two metal ions affect BK stability and proneness to degradation. We think that these issues
14
15 have to be addressed to better define the role of BK and metal ions in AD and, more generally, to
16
17 ascertain if the interaction of BK with metal ions can have an effect on BK functions. For these
18
19 reasons, here we have applied mass spectrometry (MS), circular dichroism (CD) as well as
20
21 computational methods in order to assess if copper and zinc have the ability to modulate BK
22
23 conformation and oligomerization or have an effect on its stability and proneness to degradation by
24
25 insulin-degrading enzyme (IDE).²⁷ Moreover, The biochemical analyses of BK effects on
26
27 monocyte/macrophage cell culture (THP-1 Cell Line human) in line with the metals effect on BK
28
29 conformation, showed that the presence of copper can affect the signaling cascade mediated by the
30
31 BK receptors.
32
33
34
35
36

37 **Experimental**

38 *Materials and methods*

39
40 IDE, wild type recombinant, was purchased from GIOTTO Biotech srl. BK and all the other
41
42 reactants were purchased from SIGMA-ALDRICH.
43
44

45
46 The enzymatic digestions of BK by IDE were carried out as follows. The peptide at various
47
48 concentrations was incubated with IDE (8ng/μl) in 10 mM MOPS (pH 7.4) at 37°C, in the presence
49
50 or absence of the metal ion (copper(II) or zinc(II)) for 60 min. In order to stop the enzymatic
51
52 reaction, a 10% solution in trifluoroacetic acid (TFA) was added to the different aliquots in order to
53
54 achieve a final concentration of TFA of 0.2%. Sample solutions were purified by ZIPTIPC18 and
55
56
57
58
59
60

1
2
3 after dilution with 50 μ l of water and 50 μ l of Methanol were injected into the MS ion source at a
4
5 flow-rate of 5 μ l/min, using nitrogen as drying gas.
6
7

8 9 10 *Computational analysis*

11 The BK peptide underwent 10 ns of parallel tempering (PT) simulations in explicit solvent, after
12 have been equilibrated through 2 ns of MD in explicit solvent. GROMACS 4.5.6 package²⁸ was
13 used. The overall charge of the system was neutralized by adding 2 chloride ions. Periodic
14 boundary conditions were applied. The AMBER99SB²⁹ force field was used for the biomolecules
15 and counter ions, and the TIP3P³⁰ force field was used for water molecules. Electrostatic
16 interactions were calculated using the Particle Mesh Ewald method.³¹ A cutoff (0.9 nm) was used
17 for the Lennard-Jones interactions. The time-step was set to 2 fs. All bond lengths were constrained
18 to their equilibrium values using the SHAKE³² algorithm for water and the LINCS³³ algorithm for
19 the peptide. We simulated 64 replicas distributed in the temperature range 300-400 K following a
20 geometric progression. All replicas were simulated in NVT ensemble using a stochastic
21 thermostat³⁴ with a coupling time of 0.1 ps. A thermostat that yields the correct energy fluctuations
22 of the canonical ensemble is crucial in parallel tempering simulations.³⁵ Exchanges were attempted
23 every 0.1 ps. The method of Daura and Van Gunsteren³⁶ was used in post-processing phase to
24 cluster the resulting trajectories, with a cutoff of 3 Å calculated on the backbone atoms as
25 implemented in the clustering utility provided in the GROMACS package.²⁸
26
27

28 To the former clusters were coordinated to Zn²⁺ and Cu²⁺ in a 1:1 and 2:1 BK:metal stoichiometric
29 ratio. The coordination geometries were optimized at the HF level of theory within the 6-31G**
30 basis sets through the Gaussian 09 revision D.01 package³⁷ with a root mean square displacement of
31 10-3 Å. ECD spectra were calculated using the DICHROCALC platform.³⁸
32
33
34
35
36
37
38
39
40
41
42
43
44

45 46 47 48 49 50 51 52 53 54 55 56 *Mass Spectrometry* 57 58 59 60

ESI-MS experiments were performed by using a Finnigan LCQ DECA XP PLUS ion trap spectrometer operating in the positive ion mode and equipped with an orthogonal ESI source (Thermo Electron Corporation, USA). The mass spectrometer operated with a capillary voltage of 46 V and capillary temperature of 250°C, while the spray voltage was 4.3 kV. In the presence of Cu²⁺, the BK-metal ion complex is very sensitive to the ionization potentials, so that, if a high potential (≥1.5 kV) is used, the copper(II) is reduced to copper(I), a behaviour already observed for other copper complexes (see figure 1S).³⁹

Circular Dichroism spectroscopy

Far-UV CD spectra of BK were recorded with a Jasco J-810 spectropolarimeter equipped with a Peltier thermally controlled cuvette holder (JASCO PTC- 348). BK concentrations used in CD experiments were in the range of 35 – 100 μM. CD spectra were recorded using a 0.5-cm path length quartz cuvette, from 260 – 190 nm, at 0.1 nm data pitch, 50 nm/min, with a response time of 2 s. All spectra, corresponding to an average of 10 scans, were base-line-corrected by subtracting the signal of the buffer from the CD of the sample. CD curves were recorded in pure water and the pH was adjusted to neutrality by adding NaOH or H₂SO₄. CD spectra are expressed as the mean residue molar ellipticity⁴⁰ [θ] expressed in deg cm² dmol⁻¹:

$$[\theta] = \frac{CD \times 100 \times M}{C \times l \times n} \quad (1)$$

where CD is the ellipticity in degrees, l is the optical path in cm, M is the molecular weight, n is the number of residues and C is the concentration in mg/ml.

Cell cultures

The human monocytic leukemia cell line THP-1 was grown in RPMI 1640 culture medium (Lonza, Switzerland) supplemented with 10% of fetal bovine serum (FBS; Invitrogen, UK.) and 1% of

1
2
3 penicillin/streptomycin(P/S) (Lonza, Switzerland) at 37 °C in 5% CO₂ in a humidified incubator.
4
5 LPS (E. coli 0111:B4) was purchased from Sigma.
6
7
8

9 10 *Macrophage differentiation and stimulation*

11 The mature macrophage-like state was induced by treating THP-1 monocytes for 1 week with 100 ng
12 ml⁻¹ phorbol 12-myristate 13-acetate (PMA; Sigma Chemical) in 35 mm cell culture plates
13 (NUNC, Denmark) with 3 ml cell suspension in each well. It has been demonstrated that this
14 differentiation method of THP-1 cells resulted in the expression of macrophage specific surface
15 markers CD11b and CD36 and also phagocytic activity.⁴¹ Differentiated, plastic-adherent cells were
16 washed with RPMI 1640 medium without PMA but containing 2% FBS and 1% P/S. THP-1
17 monocytes (undifferentiated cells) and THP-1 macrophages (differentiated cells) were treated with
18 BK, BK preincubated for 1 hour with copper or zinc (ratio BK:metal=1:2) or with 0.5 µg/ml LPS.
19 RPMI 1640 medium containing 2% FBS and 1% P/S was used as a control. Both types of cells were
20 harvested at two different time points 15 min and 20h to investigate phosphorylation and
21 inflammatory pathways. The experiments were performed using 3-4 independent cell culture
22 preparations cells.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 *MTT Assay*

42 Cell viability of undifferentiated THP-1 (monocytes) was defined as the reduction in MTT [3-(4,5-
43 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (Sigma-Aldrich). Living, metabolically
44 active cells reduce the soluble yellow tetrazolium salt MTT, yielding dark blue water-insoluble
45 formazan crystals. MTT was dissolved at a concentration of 5 mg/mL in phosphate-buffered saline
46 (PBS) and RPMI 1640 medium with 1% P/S. Cells were seeded in 24-well plates, and cultured for
47 24h in 1ml of culture medium containing range of concentrations of tested chemicals. Briefly,
48 whole cell suspension was taken from each well and centrifuged 5 min at 600 g. Supernatant was
49 eliminated, and the pellet was incubated for 1,5 hr in 300 µL of MTT solution per well. This
50
51
52
53
54
55
56
57
58
59
60

1
2
3 solution was then replaced with 300 μ L of DMSO (Sigma-Aldrich) per well and incubated for
4
5 15min at 37°C to dissolve the crystals. Finally, absorbance at 569 nm was measured by a microplate
6
7 reader spectrophotometer (Multiskan Ascent).
8
9

10 11 *Western blot analysis*

12
13 After treatment, cells were harvested with RIPA buffer (50mM TRIS-HCl, pH 8,0, 150mM NaCl,
14
15 0,5mM EDTA, 1% Triton X-100, 0,5mM EGTA, 1% NP40) containing 2mM PMSF
16
17 (phenylmethylsulfonylfluoride), inhibitor of proteases (Sigma). Cell lysates were incubated for 30
18
19 min and centrifuged at 14000 g for 10 min. Protein concentrations were measured by Bradford
20
21 method using BSA as standard curve. Equal amounts of protein were separated by 12 % SDS-
22
23 PAGE and transferred to nitrocellulose membrane (Sigma-Aldrich). The transfers were blocked
24
25 with blocking buffer (5% BSA in TBST) at room temperature for 1 h, incubated with primary
26
27 antibodies overnight at 4°C, 1h with horseradish peroxidase-conjugated secondary antibodies. The
28
29 antibody against IL-1beta (code: ab2105, 1:1,000 dilution) and GAPDH (code: ab8245, 1:2,000
30
31 dilution) were purchased from Abcam. The antibody against pErk1/2 (code: 9106, 1:1,000) and β -
32
33 Actin (code: 4970, 1:2,000 dilution) were from Cell Signaling Technologies, Inc. Goat anti-mouse
34
35 and anti-rabbit IgG secondary antibody horseradish peroxidase-conjugated (AP181P and AP307P,
36
37 1:3,000 dilution) were purchased from Merck Millipore. Detection was conducted using enhanced
38
39 Super Signal West Pico Chemiluminescent Substrate (Thermo Scientific). Imaging and
40
41 densitometric analyses were performed by ChemiDoc Imaging System (Bio-Rad).
42
43
44
45
46
47
48
49

50 **Results**

51 52 *Mass Spectrometry*

53
54 The amino acid sequence of BK is Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg while its empirical
55
56 formula is C₅₀H₇₃N₁₅O₁₁. BK is easily ionized and detected by ESI-MS as multi-charged molecular
57
58
59
60

1
2
3 peaks (see figure 2Sa and Table 1 for the assignment). ESI-MS has been widely applied to monitor
4
5 oligomer formation in solution, as long as experimental parameters are controlled.⁴² Here,
6
7 increasing BK concentration causes the appearance of some other peaks at higher m/z values that
8
9 have been tentatively assigned to BK dimers and trimers and to other molecular species obtained
10
11 adding Arg or Arg fragments to BK monomers (figure 2Sb, figure 3Sb and Table 1). Unfortunately,
12
13 the assignment reported in Table 1 could not be verified by MS² experiments due to the intrinsic
14
15 complexity of the molecular species detected. However, it is clear that the formation of more
16
17 complex species is directly proportional to the BK concentration in solution (figure 3S). The
18
19 formation of Arg dimers as well as BK dimers in the gas phase is well known and it has been
20
21 attributed to a salt-bridge ion–zwitterionic structure that stabilizes the dimer, $C(NH_2)_2^+ - NHCH_2 -$
22
23 $CH_2 - CH_2 - CH(NH_2) - COO^- - C(NH_2)_2^+ - NH - CH_2 - CH_2 - CH_2 - CH(NH_2) - COOH$.⁴³ Here, the oligomeric
24
25 BK species reported in Table 1 are detected only for BK solutions with a concentration > 1 μ M and
26
27 their detection is directly proportional to the BK concentration used, strongly indicating their
28
29 presence in the solution phase. Interestingly, increasing the concentration of BK also induces a shift
30
31 in the multi-charged envelope detected by ESI-MS, that is shifted towards more charged ions. As
32
33 the pH was kept constant (6.5), this indicates a lowering in the pK of the protonable groups of the
34
35 molecule, due to a concentration dependent change of the electrostatic interactions of BK solutions.
36
37 To investigate if metal ions are able to alter the above suggested concentration dependent
38
39 oligomerization of BK, we have acquired mass spectra in the m/z range of, respectively, 200-1600
40
41 (figure 4S) and 2000-4000 for BK solutions containing ZnSO₄ (figure 5S) or CuSO₄ (figure 6S) as
42
43 indicated. It is not possible to draw any quantitative conclusions based on the absolute intensity of
44
45 the peaks because different species might ionize differently. However, it is acceptable to assume
46
47 that copper(II) and zinc(II) BK complexes ionize in a similar manner in the gas phase and that their
48
49 relative intensities to apo-BK could give a semi-quantitative estimation of the relative
50
51 concentrations of the species in solution.⁴⁴ Based on these two assumptions, figure 4S would
52
53 indicate that, at the same experimental conditions, the BK-Cu²⁺ complex is more abundant than the
54
55
56
57
58
59
60

1
2
3 BK-Zn²⁺ complex, the peaks at m/z 374.5, 561.2, 1121.4 and 1219.3 (see Table 1 for the
4 assignment) having a higher relative intensities in comparison to the Zn analogous ones. This result
5 is in line with the complex stabilities dictated by the Irving-Williams series, according to which
6 copper(II) complexes are thermodynamically more stable than zinc(II) ones.⁴⁵ The absence of peaks
7 in the m/z 2000-4000 range might induce to think that precipitation of the peptide is occurring upon
8 copper addition. However, in figure 7S the mass spectrum detected for BK 30 μ M and CuSO₄ 300
9 μ M in the m/z 250-1500 range is also reported and while an intense signal is detected for both apo-
10 BK and BK-copper species, the relative intensities of these species show that the formation of the
11 copper complex is copper concentration dependent as expected (for comparison see figure 4Sb)
12
13 Moreover, MS/MS experiments for the peaks at m/z 1121.4 (BK-Cu 1:1 complex) and 1122.4 (BK-
14 Zn 1:1 complex) show different features (see figure 8S). Particularly, in the case of BK-Cu complex
15 a fragment at m/z 1077.2 (loss of 44 uma, a carboxylic group) is very abundant and easily formed
16 even at low collision energy, while this is not the case for the BK-Zn complex, hinting different
17 coordination features with carboxylic groups for the two complexes. In the case of the BK-Cu,
18 MS/MS experiments show also a loss of 143.1 uma (NHCHCOOCH₂CH₂CH₂CH₂NH) to produce
19 the 978.1 uma fragment, not present in the case of BK-Zn. A detailed MS analysis of possible
20 copper(I) and copper(II) coordination features has been already reported in the literature⁴⁶ and
21 repeating such analysis here would be redundant. However, in our knowledge the effect of copper
22 and zinc ions on BK oligomerization has never been reported. Surprisingly, figure 5S and figure 6S
23 indicate that the effect of the two metal ions on the BK oligomerization might be different. Indeed,
24 MS detection of BK₂Zn and BK₃Zn species (figure 5S and Table 1) points to the presence of
25 oligomeric species in the presence of zinc ions, while in the presence of copper ions the detection of
26 these species is remarkably hindered in a concentration dependent manner (see figure 6S).
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 *Circular Dichroism*

57
58
59
60

1
2
3 To better investigate the oligomerization features of BK solutions at different concentrations
4 suggested by the MS results and how these are affected by the presence of copper and zinc ions, we
5 have performed CD experiments. Panel A of figure 1 reports the far-UV CD spectra of BK recorded
6 in pure water at pH 6.5, room temperature and at a 35 μM of peptide concentration (solid line). CD
7 spectra show two weak dichroic signals, a positive one centred at 223 nm, a negative one at 235 nm,
8 and an intense negative band at 204 nm. These CD bands are typical of a type II poly-L-proline left-
9 handed extended helix (PPII).^{47,48} The intensities and the positions of the CD bands, in the 35-100
10 μM range do not depend on peptide concentrations (see solid lines of panels A and B). The CD
11 curves recorded at 35 μM of peptide concentration are not affected by a twofold excess of Cu(II)
12 (dashed lines) or Zn(II) (dotted lines) ions. The CD spectrum of BK was insensitive to the presence
13 of excess Zn(II) also at higher peptide concentrations (100 μM). By contrast, the addition of a
14 twofold excess of Cu(II) ions to BK 100 μM induced a fourfold and threefold enhancement of the
15 intensities of CD minima observed at 204 and 234 nm respectively, but no significant deviations of
16 the positive band at 222 nm (figure 1, panel B, dashed line). Cu(II)-induced changes of CD spectra
17 of BK are evidenced only at high copper concentration, and this is accordance with a perturbed
18 association/dissociation equilibrium. In a previous report, the negative CD band observed at 234 nm
19 for apo-BK was attributed to internally hydrogen-bonded Pro7 residues.⁴⁹ However, in those early
20 experiments CD spectra were recorded at acidic pH, in which dimeric peptide structure are unlikely
21 to form. By contrast, our experiments were performed at neutral pH, and in these conditions dimeric
22 or trimeric peptide assemblies are always present as evidenced from ESI-MS results experiments.
23 Due to the hydrophobic nature of the C-terminal segment of the peptide it is plausible that peptide
24 association occur by intermolecular Phe-Phe interactions which, in turn, is expected to disrupt the
25 H-bridged structures involving Pro7 residues. This reconciles with CD spectra reported in the
26 present work in which a very weak negative CD band at 234 nm is observed. Notably, this band
27 increases in the presence of high copper concentrations. This means that copper may promote BK-
28 dissociation into monomers with a consequent increase of the negative band at 234 nm in
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 accordance with ESI-MS results and molecular simulations. Moreover, copper-dependent peptide
4 dissociation is likely to occur with a consequent increase of the structural disorder as evidenced by
5 the increase of the negative band centered at 205 nm.
6
7
8

9 10 11 *Computational analysis*

12
13 The structural motivations behind the two different effects of copper(II) and zinc(II) metal ions on
14 BK oligomerization were also investigated by computational analysis as described in the
15 experimental section. An accurate sampling of the BK conformations was initially carried out
16 through Parallel Tempering simulations.⁵⁰ We selected the main clusters which are equally
17 populated and from those we back calculated the CD spectra. The latter show a nice agreement with
18 those experimentally recorded, confirming the presence of type II poly-L-proline left-handed
19 extended helix (PPII) (see figure 9S).
20
21
22
23
24
25
26
27
28

29 From those conformations, zinc and copper were coordinated to BK in accordance with the ESI/MS
30 indications and the coordination polyhedral were predicted in the DFT framework. The
31 coordination shell is saturated through two coordination waters. The coordination polyhedron
32 moves towards a planar arrangement upon BK binding to copper(II). In these regards, BK
33 coordinates with copper(II) via the C-terminal carboxyl oxygen of asparagine, the carbonyl oxygen
34 of the N-terminal asparagine and two inner sphere water molecules. The carbonyl oxygen belonging
35 to the N-terminal Arg competes with the N-terminal amine group for the fourth coordination
36 position (figure 2b, Table 2), indeed one among the preferred ligand for copper(II).^{51,52}
37
38
39
40
41
42
43
44
45
46

47 In line with the results obtained by MS and CD analysis, upon a double excess of BK with respect
48 to zinc ion, an elongated peptide conformation is stabilized with a head-to-tail coordination
49 polyhedron (Figure 2c). Here, Zn^{2+} is coordinated to the two carboxylic groups of BK and two
50 coordination waters (Table 2). The C-terminal Arg weakly contacts the uncoordinated carboxylic
51 oxygen of a different BK unit (Figure 2c). However, upon a double excess of BK with respect to
52 copper(II) ion, the monomeric complex of copper(II) is still formed (Figures 2b and 2d) leaving
53
54
55
56
57
58
59
60

1
2
3 uncomplexed one peptide unit of BK. This indicates an unfavourable geometry experienced by
4
5 copper(II) upon coordinating two BK units, since the requirement of a planar coordination
6
7 polyhedron. A dimeric structure can instead formed through the coordination of zinc ion, since the
8
9 coordination polyhedron is favoured by a tetrahedral spatial arrangement (Figure 2c).
10

11 12 13 14 *Enzymatic degradation assay*

15
16 We have also assessed if the presence of metal ions affects BK proneness to degradation by IDE.
17
18 This enzyme was selected among all the available BK degrading enzymes because of its
19
20 involvement with AD and the deep knowledge of IDE degrading activity towards various substrates
21
22 by our group.⁵³⁻⁵⁹ In figure 10S of the Supplementary information the mass spectra recorded after
23
24 BK incubation with IDE in the presence and in the absence of copper and zinc ions are reported.
25
26 According to previously published results,^{22,60} also in this case, copper(II) strongly inhibits IDE
27
28 activity (by binding directly to the enzyme), while zinc(II), differently from other IDE substrates
29
30 such as amylin,⁶¹ does not affect BK fragmentation pattern. This result is in line with our binding
31
32 model, according to which zinc does not affect BK conformation and therefore its proneness to
33
34 degradation.
35
36
37
38
39

40 41 *Biochemical analysis*

42
43 The oligopeptide BK, produced after cleavage of kininogens by kallikreins in the plasma or
44
45 interstitial fluid, triggers its effects by the activation of two G protein coupled transmembrane
46
47 receptors, called B₁R and B₂R.⁶² B₁R is generally absent or under-expressed in physiological
48
49 conditions, has high affinity for kinin metabolites (des-⁹Arg-BK and ⁸Leu-des-⁹Arg-BK), and is
50
51 upregulated to mediate inflammatory conditions following tissue injury or under pathological states.
52
53 Conversely, B₂R is a constitutive receptor that displays higher affinity for BK (and Kallidin)
54
55 peptide, is widely distributed and mediates most biological effects of kinins.⁶³
56
57
58
59
60

1
2
3 The expression of both receptors has shown to increase in the brains of A β 1-40 treated rats,⁶⁴
4
5 whereas the blockade of B₂R has been reported to be beneficial on cognitive deficit induced by
6
7 A β 1-40.^{65,66} Therefore it is clear that any intervention that could affect the binding activity on these
8
9 receptors can produce beneficial effects against inflammatory neurodegenerative diseases. The
10
11 activated signalling pathway goes through Erk phosphorylation and leads to up-regulation of pro-
12
13 inflammatory molecules such as IL-1 β . Thus we tested the effects of metal ions (copper and
14
15 zinc) on BK activity by analysing phosphorylation and expression of these two markers
16
17 respectively. For this investigation we used the human monocytic THP-1 cell line as innate
18
19 immunity model system and we examined the BK effects on normal THP-1 with monocytic
20
21 phenotype or on activated THP-1 that shows a stronger pro-inflammatory response as result of B₁R
22
23 up-regulation.⁶⁷ THP-1 is a human leukemic cell line with monocytic nature that can be
24
25 pathogenically challenged to initiate an inflammatory response. LPS stimulated THP-1 cells
26
27 incubated with the bacterial endotoxin, lipopolysaccharide (LPS), can produce an inflammatory
28
29 response with increase of IL-1 β secretion through a PKA-dependent mechanism.⁶⁸
30
31
32

33
34 To ascertain any toxic effect of BK, a dose response experiment was first performed to test the cell
35
36 viability after treatment with BK, BK-Cu(II) and Cu(II) using a range of concentrations known to
37
38 be effective. The cell cultures were fully viable at all concentrations used allowing further tests at
39
40 the higher dosage (figure 3). ERK phosphorylation is considered a good marker of
41
42 neuroinflammatory signalling cascade activation,⁶⁹ and was thus analyzed in cell cultures treated
43
44 with different preparations of BK.
45

46
47 Undifferentiated monocyte cell cultures were treated with the higher not toxic dose of BK alone
48
49 (50 μ M), BK preincubated in combination with copper or zinc (1 hour, ratio 1:2) or with 0.5 μ g/ml
50
51 LPS as positive control. After 15 min of treatments the Western blot analyses of phosphorylated
52
53 ERK (pERK) showed a weak cell culture response. However it was possible to measure a 70%
54
55 increase of pERK after 15 minutes of BK treatment, that was abolished by BK preincubation with
56
57 two fold copper (100 μ M, 1 hour) and only partially by BK preincubation with zinc (figure 4A).
58
59
60

1
2
3 Moreover, to verify whether the effects on signalling cascade are followed by corresponding effects
4 on pro-inflammatory cytokines synthesis, we performed the analyses of IL-1 beta expression after
5 20 hours of treatment. As expected, the western blot analyses showed an up-regulation in the
6 presence of BK (+100%) and this effect was counteracted by BK preincubation with metals,
7 particularly with copper (figure 4B).
8

9
10
11
12
13
14 The treatments of pre-activated THP-1 monocytes, that typically show a macrophagic phenotype,
15 more clearly reproduced the observed effects. Indeed we measured a more intense BK induction of
16 ERK phosphorylation (+100%), and this effect was strongly reduced after treatment with BK
17 preincubated with copper. The minor effect of the BK preincubated in the presence of zinc, with
18 respect to the presence of copper, was again observed, thus confirmed (figure 5A). Similarly IL-
19 1beta up-regulation by treatment with BK (+500%) was abolished by preincubation of BK in the
20 presence of copper, but only weakly inhibited in the presence of zinc (figure 5B).
21
22
23
24
25
26
27
28
29
30
31

32 Discussion

33
34 We have observed two different effects of copper(II) and zinc(II) metal ions on BK conformation
35 and oligomerization. MS and CD experiments indicate that copper(II), differently from zinc(II), is
36 able to hinder BK oligomerization and the results are in line with the computational analysis.
37
38

39
40 The biochemical data support the hypothesis that conformational changes observed upon
41 copper/BK binding are responsible of significant differences of the metal effects on
42 proinflammatory activity of BK.
43
44
45
46

47
48 Several evidences support the notion of Kallikrein-Kinin System (KKS) involvement in AD. The
49 contact/kinin system is activated in cerebrospinal fluid (CSF) of patients with AD by the cleavage
50 of high molecular mass kininogen, providing the link between the KKS and the pathogenesis of
51 AD.^{70,71} This correlation has been also supported by the observation that A β peptides infusion can
52 trigger an increase in kinin concentration in the cerebrospinal fluid of animals, proving that an
53
54
55
56
57
58
59
60

1
2
3 enhanced activation of KKS takes part in the inflammatory driven toxicity in AD.⁷² In this respect,
4
5 amongst the mechanisms that are altered in AD, activation of KKS has been correlated to up-
6
7 regulation of bradykinin receptors,⁷³ secretion of the amyloid precursor protein,⁷⁴ and activation of
8
9 MAPK, Erk1 and Erk2 phosphorylation, a mechanism found to early distinguish AD from other
10
11 dementias.⁶⁹

12
13
14 Here we demonstrated that copper binding can change BK conformation and this in turn can
15
16 challenge a BK signalling fault, measured as reduction in Erk1/2 phosphorylation and IL-1 β
17
18 expression, that is likely related to failure or defective BK binding to its receptors. This is indeed
19
20 evidenced by the more intense and significant effects observed on THP-1 differentiated cells which
21
22 present a typical macrophagic phenotype, and higher BK receptors expression hence.⁷⁵

23
24
25
26 AD is the most concerned neurodegenerative disease with respect to copper levels and effects on
27
28 the specific A β peptide conformational changes, including in particular the inflammatory status that
29
30 significantly contributes to the progression and effects of this devastating disease. Indeed, new data
31
32 from preclinical and clinical studies have established that immune system-mediated actions in fact
33
34 contribute to and drive AD pathogenesis. These insights have suggested both novel and well-
35
36 defined potential therapeutic targets for AD, including microglia and several cytokines.⁷⁶
37
38 Nonetheless, we didn't find direct effects of BK on A β toxicity (see suppl. 11S), but the significant
39
40 copper effects on BK conformation and activity observed herein provide a new perspective on the
41
42 consequences of copper dishomeostasis in those neurodegenerative diseases, like AD, where the
43
44 effects of protein misfolding are associated to an inflammatory status, now recognized to be not
45
46 simply a collateral condition.
47
48
49
50
51
52

53 **Conclusions**

54
55
56
57
58
59
60

In this work we have been able to correlate a metal induced effect on BK conformation and oligomerization with a change in BK activity measured as reduction in Erk1/2 phosphorylation and IL-1 β expression, that is likely related to failure or defective BK binding to its receptors.

BK is known to be involved in many crucial biological processes, but here particular attention has been devoted to its role in chronic inflammatory diseases, included neurodegenerative diseases like AD. Since copper, and more generally metals, dyshomeostasis has been claimed to be responsible of several related complains, the copper effects on BK conformation and activity observed herein can open new potentiality in the treatment of neuroinflammatory diseases by management of copper level and distribution.

Acknowledgements

We thank PRIN 2008R23Z7K and FIR 2014 9DD800 for financial support.

Tables

BK species	Experimental (<i>m/z</i>)	Calculated Isotopic (<i>m/z</i>)
$3\text{BK} + \text{ArgPhe} - \text{C}_6\text{H}_6 + \text{H}^+$	3422.8	3422.9
$3\text{BK} + \text{CH}_2\text{CH}_2\text{CH}_2\text{NHCNHNH} - \text{H}^+ + \text{Zn}^{2+}$	3340.7	3340.7
$3\text{BK} + \text{CH}_2\text{CH}_2\text{CH}_2\text{NHCNHNH} - \text{H}^+ + \text{Cu}^{2+}$	3339.7	3339.7
$3\text{BK} + \text{CH}_2\text{CH}_2\text{CH}_2\text{NHCNHNH} + \text{H}^+$	3278.6	3278.8
$3\text{BK} + \text{H}^+$	3179.7	3179.7
$2\text{BK} + \text{ArgPhe} - \text{C}_6\text{H}_6 + \text{H}^+$	2363.0	2363.3
$2\text{BK} + 2\text{Zn}^{2+} + \text{CH}_2\text{CH}_2\text{CH}_2\text{NHCNH}_2\text{NH}_2 - 3\text{H}^+$	2345.0	2345.0

2BK + Zn ²⁺ + CH ₂ CH ₂ CH ₂ NHCNHNH ₂ - H ⁺	2282.1	2282.1
2BK + Cu ²⁺ + CH ₂ CH ₂ CH ₂ NHCNHNH ₂ - H ⁺	2281.1	2281.1
2BK + CH ₂ CH ₂ CH ₂ NHCNHNH + H ⁺	2219.0	2219.2
2BK + Zn ²⁺ - H ⁺	2182.1	2182.0
2BK + H ⁺	2120.3	2120.1
BK + Zn ²⁺ - H ⁺ + CH ₂ CH ₂ CH ₂ NHCNHN	1220.2	1220.5
BK + Cu ²⁺ - H ⁺ + CH ₂ CH ₂ CH ₂ NHCNHN	1219.3	1219.5
BK + Arg - H ₂ O - 4H + H ⁺	1212.1	1212.7
BK + Zn ²⁺ - H ⁺	1122.4	1122.5
BK + Cu ²⁺ - H ⁺	1121.4	1121.5
BK + Na ⁺	1082.5	1082.5
BK + H ⁺	1060.5	1060.6
ArgProProGlyPheSerProPhe + H ⁺	904.4	904.4
BK + Arg - H ₂ O - 4H + 2H ⁺	606.6	607.3
BK + Cu ²⁺	561.2	561.2
BK + 2H ⁺	530.9	530.8
BK + H ⁺ + Na ⁺	541.8	541.8
BK + 2H ⁺ + K ⁺	367.0	366.7
BK + 3H ⁺	354.1	354.2
BK + Zn ²⁺ + H ⁺	374.8	374.8
BK + Cu ²⁺ + H ⁺	374.5	374.5

Table 1

Zn²⁺-BK			
Bond	Bond length (Å)	Angle type	Angle (degree)
Zn ²⁺ -NH ₂	2.17	OH ₂ -Zn ²⁺ -NH ₂	117.88
Zn ²⁺ -OCO	1.97	OH ₂ -Zn ²⁺ -NH ₂	115.19
Zn ²⁺ -OH ₂	2.09	OH ₂ -Zn ²⁺ -OH ₂	119.79
Zn ²⁺ -OH ₂	2.09	OH ₂ -Zn ²⁺ -OCO	97.23
Cu²⁺-BK			
Bond	Bond length (Å)	Angle type	Angle (degree)
Cu ²⁺ -NH ₂	2.35	NH ₂ -Cu-OH ₂	104.08
Cu ²⁺ -OC	2.02	OH ₂ -Cu ²⁺ -OC	95.92
Cu ²⁺ -OCO	1.95	OH ₂ -Cu ²⁺ -OC	82.10
Cu ²⁺ -OH ₂	2.02	OH ₂ -Cu ²⁺ -OH ₂	139.54
Cu ²⁺ -OH ₂	2.03	OH ₂ -Cu ²⁺ -OCO	91.75
Zn²⁺-(BK)₂			
Bond	Bond length (Å)	Angle type	Angle (degree)
Zn ²⁺ -OCO	1.94	OH ₂ -Zn ²⁺ -OCO	108.13
Zn ²⁺ -OCO	1.91	OH ₂ -Zn ²⁺ -OCO	104.62
Zn ²⁺ -OH ₂	2.06	OH ₂ -Zn ²⁺ -OH ₂	103.22
Zn ²⁺ -OH ₂	2.07	OCO-Zn ²⁺ -OCO	129.43

Table 2

References

- ¹ P. Kaur, A. Muthuraman and M. Kaur, The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives, *ACS Chem. Neurosci.* 2015, **6**, 508–521.
- ² N.P. Mason, M. Petersen, C. Mélot, E.V. Kim, A. Aldashev, A. Sarybaev, M.M. Mirrakhimov and R. Naeije, Changes in plasma bradykinin concentration and citric acid cough threshold at high altitude, *Wilderness Environ. Med.* 2009, **20**, 353–358.
- ³ L.R. Dalemar, Y.J. Ivy Jong, B. Wilhelm and N.L. Baenziger, Protein kinases A and C rapidly modulate expression of human lung fibroblast B2 bradykinin receptor affinity forms, *Eur. J. Cell Biol.* 1996, **69**, 236–244.
- ⁴ B. Lacoste, X.-K. Tong, K. Lahjouji, R. Couture and E. Hamel, Cognitive and cerebrovascular improvements following kinin B1 receptor blockade in Alzheimer's disease mice, *J. Neuroinflammation* 2013, **10**, 57.
- ⁵ F.A. Amaral, M.T.R. Lemos, K.E. Dong, M.F.Q.P. Bittencourt, A.L. Caetano, J.B. Pesquero, T.A. Viel and H.S. Buck, Participation of kinin receptors on memory impairment after chronic infusion of human amyloid- β 1-40 peptide in mice. *Neuropeptides* 2010, **44**, 93–97.
- ⁶ C.M. Costa-Neto, P. Dillenburg-Pilla, T.A. Heinrich, L.T. Parreiras-e-Silva, M.G. Pereira, R.I. Reis and P.P.C. Souza, Participation of kallikrein-kinin system in different pathologies, *Int. Immunopharmacol.* 2008, **8**, 135–142.
- ⁷ K. Walker, M. Perkins and A. Dray, Kinins and kinin receptors in the nervous system, *Neuroch. Int.* 1995, **26**, 1–26.
- ⁸ T.A. Viel and H.S. Buck, Kallikrein-Kinin system mediated inflammation in Alzheimer's disease in vivo, *Cur. Alzheimer Res.* 2011, **8**, 59–66.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
-
- ⁹ L.M. Iores-Marçal, T.A. Viel, H.S. Buck, V.A. Nunes, A.J. Gozzo, I. Cruz-Silva, A. Miranda, K. Shimamoto, N. Ura and M.S. Araujo, Bradykinin release and inactivation in brain of rats submitted to an experimental model of Alzheimer's disease, *Peptides* 2006, **27**, 3363–3369.
- ¹⁰ E. Malito, L.A. Ralat, M. Manolopoulou, J.L. Tsay, N.L. Wadlington and W.-J. Tang, Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme, *Biochemistry* 2008, **47**, 12822–12834.
- ¹¹ G. Grasso, P. Mielczarek, M. Niedziolka and J. Silberring, Metabolism of cryptic peptides derived from neuropeptide FF precursors: the involvement of insulin-degrading enzyme, *Int. J. Mol. Sci.* 2014, **15**, 16787–16799.
- ¹² D.K. Lahiri, D.M. Chen, P. Lahiri, S. Bondy and G. H. Greig, Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases, *Ann. N. Y. Acad. Sci.*, 2005, **1056**, 430–449.
- ¹³ M.A. Lovell, J.D. Robertson, W.J. Teesdale, J.L. Campbell and W.R. Markesbery, Copper, iron and zinc in Alzheimer's disease senile plaques, *J. Neurol. Sci.*, 1998, **158**, 47–52.
- ¹⁴ P.J. Crouch and K.J. Barnham. Therapeutic redistribution of metal ions to treat Alzheimer's disease. *Acc. Chem. Res.* 2012, **45**, 1604–1611.
- ¹⁵ P.A. Adlard, L. Bica, A.R. White, M. Nurjono, G. Filiz, P.J. Crouch, P.S. Donnelly, R. Cappai, D.I. Finkelstein and A.I. Bush. Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease. *PLoS One* 2011, **6**, e17669.
- ¹⁶ P. Lei, S. Ayton, A.T. Appukuttan, I. Volitakis, P.A. Adlard, D.I. Finkelstein and A.I. Bush. Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. *Neurobiol. Dis.* 2015, **81**, 168–175.
- ¹⁷ A. I. Bush and R. E. Tanzi, Therapeutic for Alzheimer's disease based on the metal hypothesis, *Neurotherapeutics*, 2008, **5**, 421–432.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
-
- ¹⁸ G. Arena, R. Fattorusso, G. Grasso, G.I. Grasso, C. Isernia, G. Malgieri, D. Milardi and E. Rizzarelli. Zinc(II) complexes with ubiquitin: speciation, affinity and binding features. *Chem.- Eur. J.* 2011, **17**, 11596–11603.
- ¹⁹ D. Milardi, F. Arnesano, G. Grasso, A. Magrì, G. Tabbi, S. Scintilla, G. Natile, Ubiquitin stability and the Lys 63 linked polyubiquitination site are compromised on copper binding, *Angew. Chem. Int. Edit.* 2007, **46**, 7993–7995.
- ²⁰ G. Arena, F. Bellia, G. Frasca, G. Grasso, V. Lanza, E. Rizzarelli and G. Tabbi, Inorganic stressors of ubiquitin, *Inorg. Chem.* 2013, **52**, 9567–9573.
- ²¹ A. Travaglia, D. La Mendola, A. Magrì, A. Pietropaolo, V.G. Nicoletti, G. Grasso, G. Malgieri, R. Fattorusso, C. Isernia and E. Rizzarelli. Zn(II) interactions with BDNF N-terminal peptide fragments: inorganic features and biological perspectives. *Inorg. Chem.* 2013, **52**, 11075–11083.
- ²² G. Grasso, A. Pietropaolo, G. Spoto, G. Pappalardo, G.R. Tundo, C. Ciaccio, M. Coletta and E. Rizzarelli, Copper(I) and copper(II) inhibit A β peptides proteolysis by insulin-degrading enzyme differently: implications for metallostasis alteration in Alzheimer's disease, *Chem.- Eur. J.* 2011, **17**, 2752–2762.
- ²³ B. Ivanova and M. Spiteller, Coordination ability of bradykinin with ZnII- and AgI-metal ions – Experimental and theoretical study, *Inorg. Chimica Acta* 2012, **392**, 211–220.
- ²⁴ M. Prudent and H.H. Girault, On-line electrogeneration of copper–peptide complexes in microspray mass spectrometry, *J. Am. Soc. Mass Spectrom.* 2008, **19**, 560–568.
- ²⁵ J. Dong, R.W. Vachet, Coordination sphere tuning of the electron transfer dissociation behavior of Cu(II)–peptide complexes, *J. Am. Soc. Mass Spectrom.* 2012, **23**, 321–329.
- ²⁶ B.A. Cerda, L. Cornett and C. Wesdemiotis, Probing the interaction of alkali and transition metal ions with bradykinin and its des-arginine derivatives via matrix-assisted laser desorption/ionization and postsource decay mass spectrometry, *Int. J. Mass Spectrom.* 1999, **193**, 205–226.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
-
- ²⁷ G. Malgieri and G. Grasso, The clearance of misfolded proteins in neurodegenerative diseases by zinc metalloproteases: an inorganic perspective, *Coordin. Chem. Rev.* 2014, **260**, 139–155.
- ²⁸ B. Hess, C. Kutzner, D. van der Spoel and D. Lindahl, GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation, *J. Chem. Theory Comp.* 2008, **4**, 435–447.
- ²⁹ V. Hornak, R. Abel, A. Okur, B. Strockbine, A. Roitberg and C. Simmerling, Comparison of multiple Amber force fields and development of improved protein backbone parameters, *Proteins* 2006, **65**, 712–725.
- ³⁰ W.L. Jorgensen, J. Chandrasekhar, J.D. Madura, R.W. Impey and M.L. Klein, Comparison of simple potential functions for simulating liquid water, *J. Chem. Phys.* 1983, **79**, 926–935.
- ³¹ U. Essmann, L. Perera, M.L. Berkowitz, T. Darden, H. Lee and L.G. Pedersen, A smooth particle mesh Ewald method, *J. Chem. Phys.* 1995, **103**, 8577–8593.
- ³² S. Miyamoto and P.A. Kollman, SETTLE: an analytical version of the SHAKE and RATTLE algorithms for rigid water models, *J. Comp. Chem.* 1992, **13**, 952–962.
- ³³ B. Hess, P-LINCS: A parallel linear constraint solver for molecular simulation, *J. Chem. Theory Comput.* 2008, **4**, 116–122.
- ³⁴ G. Bussi, D. Donadio and M. Parrinello, Canonical sampling through velocity rescaling, *J. Chem. Phys.* 2007, **126**, 014101.
- ³⁵ E. Rosta, N.V. Buchete and G. Hummer. Thermostat artifacts in replica exchange molecular dynamics simulations. *J. Chem. Theory Comput.* 2009, **5**, 1393–1399.
- ³⁶ X. Daura, K. Gademann, B. Jaun, D. Seebach, W.F. van Gunsteren and A.E. Mark, Peptide folding: when simulation meets experiment, *Angew. Chem. Int. Edit.* 1999, **38**, 236–240.
- ³⁷ Gaussian 09, Revision D.01, M.J. Frisch et al. *Gaussian, Inc., Wallingford CT*, 2009.
- ³⁸ B.M. Bulheller and J.D. Hirst, DichroCalc -Circular and Linear Dichroism Online, *Bioinformatics*, 2009, **25**, 539–540.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
-
- ³⁹ L. Gianelli, V. Amendola, L. Fabbri, P. Pallavicini and G. Mellerio, Investigation of reduction of Cu(II) complexes in positive-ion mode electrospray mass spectrometry, *Rapid Commun. Mass Spectrom.* 2001, **15**, 2347–2353.
- ⁴⁰ D. Grasso, C. La Rosa, D. Milardi and S. Fasone, The effects of scan rate and protein concentration on DSC thermograms of bovine superoxide dismutase, *Thermochimica Acta* 1995, **265**, 163–175.
- ⁴¹ L. Zhou, L.H. Shen, L.H. Hu, H. Ge, J. Pu, D.J. Chai, Q. Shao, L. Wang, J.Z. Zeng and B. He, Retinoid X receptor agonists inhibit phorbol-12-myristate-13-acetate (PMA)-induced differentiation of monocytic THP-1 cells into macrophages. *Mol. Cell. Biochem.* 2009, **335**, 283–289.
- ⁴² E.J. Nettleton, P. Tito, M. Sunde, M. Bouchard, C.M. Dobson and C.V. Robinson, Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry. *Biophys J.* 2000, **79**, 1053–1065.
- ⁴³ C. Lifshitz, A review of gas-phase H/D exchange experiments: the protonated arginine dimer and bradykinin nonapeptide systems, *Int. J. Mass Spectrom.* 2004, **234**, 63–70.
- ⁴⁴ Z.L. Cheng, K.W.M. Siu, R. Guevremont and S.S. Berman, Electrospray mass spectrometry: a study on some aqueous solutions of metal salts, *J. Am. Soc. Mass Spectrom.* 1992, **3**, 281–288.
- ⁴⁵ G. Grasso, A. Magri, F. Bellia, A. Pietropaolo, D. La Mendola and E. Rizzarelli, The copper(II) and zinc(II) coordination mode of HExxH and HxxEH motif in small peptides: the role of carboxylate location and hydrogen bonding network, *J. Inorg. Biochem.* 2014, **130**, 92–102.
- ⁴⁶ M. Prudent and H. H. Girault, On-line electrogeneration of copper–peptide complexes in microspray mass spectrometry, *J. Am. Soc. Mass Spectrom.* 2008, **19**, 560–568.
- ⁴⁷ A.S. Tatham, A.F. Drake and P.R. Shewry, Conformational studies of a synthetic peptide corresponding to the repeat motif of C hordein, *Biochem. J.* 1989, **259**, 471–476.
- ⁴⁸ G. Di Natale, G. Pappalardo, D. Milardi, M.F.M. Sciacca, F. Attanasio, D. La Mendola and E. Rizzarelli, Membrane interactions and conformational preferences of human and avian prion N-

terminal tandem repeats: the role of copper(II) ions, pH, and membrane mimicking environments, *J. Phys. Chem. B* 2010, **114**, 13830–13838.

⁴⁹ J.R. Cann, J.M. Stewart and G.R. Matsueda, A circular dichroism study of the secondary structure of bradykinin. *Biochemistry* 1973, **12**, 3780–3788.

⁵⁰ Y. Sugita and Y. Okamoto. Replica-exchange molecular dynamics method for protein folding. *Chem. Phys. Lett.* 1999, **314**, 141–151.

⁵¹ A. Travaglia, D. La Mendola, A. Magri, V.G. Nicoletti, A. Pietropaolo and E. Rizzarelli. Copper, BDNF and its N-terminal domain: inorganic features and biological perspectives. *Chem. Eur. J.* 2012, **18**, 15618–15631.

⁵² R. De Ricco, D. Valensin, S. Dell'Acqua, L. Casella L, P. Dorlet P, P. Faller and C. Hureau. Remote His50 acts as a coordination switch in the high-affinity N-terminal centered copper(II) site of α -synuclein. *Inorg. Chem.* 2015, **54**, 4744–4751.

⁵³ F. Bellia, A. Pietropaolo and G. Grasso, Formation of insulin fragments by insulin-degrading enzyme: the role of zinc(II) and cystine bridges. *J. Mass Spectrom.* 2013, **48**, 135–140

⁵⁴ G. Grasso, E. Rizzarelli and G. Spoto, The proteolytic activity of insulin-degrading enzyme: a mass spectrometry study. *J. Mass Spectrom.* 2009, **44**, 735–741.

⁵⁵ C. Ciaccio, G.F. Tundo, G. Grasso, G. Spoto, D. Marasco, M. Ruvo, S. Marini, E. Rizzarelli and M. Coletta, Somatostatin: a novel substrate and a modulator of insulin degrading enzyme activity. *J. Mol. Biol.* 2009, **385**, 1556–1567.

⁵⁶ G. Grasso, A.I. Bush, R. D'Agata, E. Rizzarelli and G. Spoto, Enzyme solid-state support assays: a surface plasmon resonance and mass spectrometry coupled study of immobilized insulin degrading enzyme. *Eur. Biophys. J.* 2009, **38**, 407–414.

⁵⁷ G. Grasso, E. Rizzarelli and G. Spoto, How the binding and degrading capabilities of insulin degrading enzyme are affected by ubiquitin. *BBA-Proteins and Proteomics* 2008, **1784**, 1122–1126.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
-
- ⁵⁸ G. Grasso, E. Rizzarelli and G. Spoto, AP-MALDI/MS complete characterization of insulin fragments produced by the interaction of IDE with bovine insulin. *J. Mass Spectrom.* 2007, **42**, 1590–1598.
- ⁵⁹ G. Grasso, C. Satriano and D. Milardi, A neglected modulator of insulin-degrading enzyme activity and conformation: the pH. *Biophys. Chem.* 2015, **203-204**, 33–40.
- ⁶⁰ G. Grasso, F. Salomone, G.R. Tundo, G. Pappalardo, C. Ciaccio, G. Spoto, A. Pietropaolo, M. Coletta and E. Rizzarelli, Metal ions affect insulin-degrading enzyme activity, *J. Inorg. Biochem.* 2012, **117**, 351–358.
- ⁶¹ F. Bellia and G. Grasso, The role of copper(II) and zinc(II) in the degradation of human and murine IAPP by insulin-degrading enzyme, *J. Mass Spectrom.* 2014, **49**, 274–279.
- ⁶² D. Regoli and J. Barabe, Pharmacology of bradykinin and related kinins, *Pharmacol. Rev.* 1980, **32**, 1–46.
- ⁶³ S.A. Mathis, N.L. Criscimagna and L.M.F. Leeb-Lundberg, B1 and B2 kinin receptors mediate distinct patterns of intracellular Ca²⁺ signaling in single cultured vascular smooth muscle cells. *Mol. Pharmacol.* 1996, **50**, 128–139.
- ⁶⁴ T.A. Viel, A. Lima Caetano, A.G. Nasello, C.L. Lancelotti, V.A. Nunes, M.S. Araujo and H.S. Buck, Increases of kinin B1 and B2 receptors binding sites after brain infusion of amyloid-beta 1–40 peptide in rats. *Neurobiol. Aging* 2008, **29**, 1805–1814.
- ⁶⁵ R.D. Prediger, R. Medeiros, P. Pandolfo, F.S. Duarte, G.F. Passos, J.B. Pesquero, M.M. Campos, J.B. Calixto and R.N. Takahashi. Genetic deletion or antagonism of kinin B(1) and B(2) receptors improves cognitive deficits in a mouse model of Alzheimer’s disease. *Neuroscience* 2008, **151**, 631–643.
- ⁶⁶ M.A. Bicca, R. Costa, G. Loch-Neckel, C.P. Figueiredo, R. Medeiros and J.B. Calixto. B2 receptor blockage prevents Aβ-induced cognitive impairment by neuroinflammation inhibition *Behav. Brain Res.* 2015, **278**, 482–491.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
-
- ⁶⁷ S. Tsuchiya, M. Yamabe, Y. Yamaguchi, Y. Kobayashi, T. Konno and K. Tada. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). *Int. J. Cancer*. 1980, **26**, 171–176.
- ⁶⁸ L.A. Grisanti, J. Evanson, E. Marchus, H. Jorissen, A.P. Woster, W. DeKrey, E.R. Sauter, C.K. Combs and J.E. Porter. Pro-inflammatory responses in human monocytes are β 1-adrenergic receptor subtype dependent. *Mol. Immunol.* 2010, **47**, 1244–1254.
- ⁶⁹ T.K. Khan and D.L. Alkon. An internally controlled peripheral biomarker for Alzheimer's disease: Erk1 and Erk2 responses to the inflammatory signal bradykinin. *Proc. Natl. Acad. Sci.* 2006, **103**, 13203–13207.
- ⁷⁰ L. Bergamaschini, C. Donarini, G. Gobbo, L. Parnetti and V. Gallai. Activation of complement and contact system in Alzheimer's disease. *Mech. Ageing Dev.* 2001, **122**, 1971–1983.
- ⁷¹ T.A. Viel and H.S. Buck. Abeta and BK kallikrein-kinin system mediated inflammation in Alzheimer's disease in vivo. *Curr. Alzheimer Res.*, 2011, **8**, 59–66.
- ⁷² L.M. Iores-Marçal, T.A. Viel, H.S. Buck, V.A. Nunes, A.J. Gozzo, I. Cruz-Silva, A. Miranda, K. Shimamoto, N. Ura and M.S. Araujo. Bradykinin release and inactivation in brain of rats submitted to an experimental model of Alzheimer's disease. *Peptides* 2006, **27**, 3363–3369.
- ⁷³ H.M. Huang, T.A. Lin, G.Y. Sun and G.E. Gibson. Increased inositol 1,4,5-Trisphosphate accumulation correlates with an up-regulation of bradykinin receptors in Alzheimer's disease. *J. Neurochem.* 1995, **64**, 761–766.
- ⁷⁴ R.M. Nitsch, C. Kim and J.H. Growdon. Vasopressin and bradykinin regulate secretory processing of the amyloid protein precursor of Alzheimer's disease. *Neurochem. Res.* 1998, **23**, 807–814.
- ⁷⁵ C.M. Bertram, S. Baltic, N.L. Misso, K.D. Bhoola, P.S. Foster, P.J. Thompson and M. Fogel-Petrovic. Expression of kinin B1 and B2 receptors in immature, monocyte-derived dendritic cells

1
2
3
4
5 and bradykinin-mediated increase in intracellular Ca^{2+} and cell migration. *J. Leukoc. Biol.* 2007, **81**,
6
7 1445–1454.

8
9 ⁷⁶ F.L. Heppner, R.M. Ransohoff and B. Becher. Immune attack: the role of inflammation in
10
11 Alzheimer disease. *Nat. Rev. Neurosci.* 2015, **16**, 358–372.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure and Table Legends

Table 1: Experimental and calculated m/z values for the BK species detected by ESI-MS from BK solutions at various concentrations with and without metal ions (Cu^{2+} and Zn^{2+}). Assignment of the peak at m/z 904.4 has been confirmed by MS/MS experiments that allow to exclude the presence of the isobar peptide HPro-Pro-Gly-Phe-Ser-Pro-Phe-ArgOH.

Table 2: Coordination parameters for the Zn^{2+} and Cu^{2+} optimized complexes with BK. Root mean square displacement during geometry optimization is 10^{-3} Å.

Figure 1: The effect of Cu(II) and Zn(II) ions on the CD signals of BK in water at neutral pH and different peptide concentrations. CD spectra of 35 μM (panel A) and 100 μM (panel B) of pure BK (solid lines) and in the presence of a twofold excess of Cu(II) (dashed lines) or Zn(II) (dotted lines) ions.

Figure 2: a) Coordination structure of Zn^{2+} complex with BK. b) Coordination structure of Cu^{2+} complex with BK. c) Coordination structure of the dimeric complex of Zn^{2+} with BK. The weak interaction between the C-terminal Arg and the carboxylic oxygen is circled. d) No dimer formation occurs with a 1:2 stoichiometric ratio of Cu^{2+} and BK.

Figure 3: Dose response experiment to test the cell viability after treatment with BK, BK-Cu(II) and Cu(II). THP-1 cell cultures (undifferentiated monocytes) were incubated with increasing concentrations of BK and BK-Cu(II) for 20h and then cell viability was measured using MTT assay. Results are presented as the means \pm SEM, the experiments were performed 3 times in triplicate.

1
2
3 **Figure 4:** Expression of A) pErk1/2 and B) IL-1 beta in THP-1 cell cultures (undifferentiated
4 monocytes) after 15 min and 20 hrs of treatment, respectively, with BK, copper or zinc alone, or
5 BK pre-incubated with metals (1 h, ratio 1:2). Results are presented as mean \pm SEM, the
6 experiments were performed 3 times in triplicate. Asterisk (*) represents the correlation significant
7 at the $p \leq 0.05$ level w.r.t. control, One-way Anova.
8
9
10
11
12
13
14
15

16 **Figure 5:** Expression of A) pErk1/2 and B) IL-1 beta in THP-1 cell cultures (differentiated
17 monocytes: macrophages) after 15 min and 20 hrs of treatment, respectively, with BK or BK pre-
18 incubated with copper or zinc (1 h, ratio 1:2). Results are presented as mean \pm SEM, the experiments
19 were performed 3 times in triplicate. Asterisk (*) represents the correlation significant at the $p \leq$
20 0.05 level w.r.t. control, One-way Anova.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: The effect of Cu(II) and Zn(II) ions on the CD signals of BK in water at neutral pH and different peptide concentrations. CD spectra of 35 μM (panel A) and 100 μM (panel B) of pure BK (solid lines) and in the presence of a twofold excess of Cu(II) (dashed lines) or Zn(II) (dotted lines) ions.
263x181mm (300 x 300 DPI)




Figure 2: a) Coordination structure of Zn²⁺ complex with BK. b) Coordination structure of Cu²⁺ complex with BK. c) Coordination structure of the dimeric complex of Zn²⁺ with BK. The weak interaction between the C-terminal Arg and the carboxylic oxygen is circled. d) No dimer formation occurs with a 1:2 stoichiometric ratio of Cu²⁺ and BK.
201x281mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3: Dose response experiment to test the cell viability after treatment with BK, BK-Cu(II) and Cu(II). THP-1 cell cultures (undifferentiated monocytes) were incubated with increasing concentrations of BK and BK-Cu(II) for 20h and then cell viability was measured using MTT assay. Results are presented as the means \pm SEM, the experiments were performed 3 times in triplicate.
189x121mm (300 x 300 DPI)




Figure 4: Expression of A) pErk1/2 and B) IL-1 beta in THP-1 cell cultures (undifferentiated monocytes) after 15 min and 20 hrs of treatment, respectively, with BK, copper or zinc alone, or BK pre-incubated with metals (1 h, ratio 1:2). Results are presented as mean \pm SEM, the experiments were performed 3 times in triplicate. Asterisk (*) represents the correlation significant at the $p \leq 0.05$ level w.r.t. control, One-way Anova.

48869x58801mm (1 x 1 DPI)




Figure 5: Expression of A) pErk1/2 and B) IL-1 beta in THP-1 cell cultures (differentiated monocytes: macrophages) after 15 min and 20 hrs of treatment, respectively, with BK or BK pre-incubated with copper or zinc (1 h, ratio 1:2). Results are presented as mean \pm SEM, the experiments were performed 3 times in triplicate. Asterisk (*) represents the correlation significant at the $p \leq 0.05$ level w.r.t. control, One-way Anova.

50241x65531mm (1 x 1 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Bradykinin (BK) is recognized to be an inflammatory mediator and recent data also support an anti-
4 inflammatory role of BK in Alzheimer's disease (AD). On the other hand, copper and zinc
5 dyshomeostasis have been demonstrated to be largely involved with AD. In this scenario, it is
6 important to understand how these metal ions interact with BK and if such interaction can affect BK
7 activity. We report here that BK conformation and oligomerization status is strongly affected by
8 copper but not zinc and this in turn affects BK activity in cells. The results obtained open to further
9 role of metal ions, particularly copper, in the development and outcome of neuroinflammatory
10 diseases.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60